Real-World data reveals how two prostate cancer drugs stack up
NCT ID NCT05968599
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical records from over 2,700 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers compared two common treatments, enzalutamide and abiraterone, to see which one helped men live longer. The goal was to understand how these drugs work in everyday medical practice, not in a controlled trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Inc
New York, New York, 10001, United States